HC Wainwright Reiterates Buy Rating for OPKO Health (NASDAQ:OPK)

HC Wainwright reaffirmed their buy rating on shares of OPKO Health (NASDAQ:OPK) in a research report report published on Wednesday morning,Benzinga reports. They currently have a $3.00 price objective on the biotechnology company’s stock.

A number of other equities analysts have also recently issued reports on OPK. Barrington Research restated an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a report on Friday, November 8th. StockNews.com raised OPKO Health from a “sell” rating to a “hold” rating in a research note on Tuesday. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $3.00 price objective on shares of OPKO Health in a research note on Tuesday, September 17th.

OPKO Health Trading Down 0.7 %

OPKO Health stock opened at $1.47 on Wednesday. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of -7.74 and a beta of 1.63. OPKO Health has a 1 year low of $0.86 and a 1 year high of $1.76. The firm’s 50 day moving average price is $1.54 and its two-hundred day moving average price is $1.50. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97.

Insider Activity

In related news, CEO Phillip Md Et Al Frost purchased 280,183 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The stock was acquired at an average cost of $1.50 per share, for a total transaction of $420,274.50. Following the completion of the acquisition, the chief executive officer now owns 211,512,405 shares in the company, valued at $317,268,607.50. This trade represents a 0.13 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders have acquired 1,304,255 shares of company stock worth $2,024,605. 47.26% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On OPKO Health

Several institutional investors and hedge funds have recently modified their holdings of the stock. CIBC Asset Management Inc increased its stake in shares of OPKO Health by 79.1% in the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 8,978 shares during the last quarter. FMR LLC increased its position in OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares during the last quarter. Algert Global LLC purchased a new stake in shares of OPKO Health during the 2nd quarter worth about $44,000. Orion Portfolio Solutions LLC acquired a new stake in shares of OPKO Health during the 3rd quarter valued at about $45,000. Finally, Private Advisor Group LLC lifted its holdings in shares of OPKO Health by 242.7% during the 3rd quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 25,000 shares during the last quarter. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.